Page 5 - Project Nextgen News Today

(CNN) — In the future, some Covid-19 vaccines may not be jabs in the arm. They could be a nasal spray or even a patch on the skin. Those are

VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust and expansive lipid nanoparticle

NIAID is conducting early phase clinical trials on select next generation vaccine candidates with the intent to identify the most effective platforms and delivery routesOCU500 will be tested as both...

In todays Research Roundup for October 9, 2023, we highlight some of the most interesting reads in global health research and development from the past week.

04.10.2023 - EMERYVILLE, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) - Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced results from all three (3) Phase 1 studies ... Seite 1

In todays Research Roundup for October 2, 2023, we highlight some of the most interesting reads in global health research and development from the past week.

Instead of pouring public funds into private industry—as the U.S. did with COVID-19 vaccines—we must build public capacity and prioritize public objectives.

By Chris Wack Gritstone bio shares were up 17% to $1.39 after the company was awarded a contract valued at up to $433 million by the Biomedical Advanced...

28.09.2023 - Provides Initial $59 Million and up to $168 Million Contingent on MilestonesNATICK, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) - ModeX Therapeutics Inc., an OPKO Health, Inc. company (NASDAQ: OPK), has been awarded a contract from the Biomedical ... Seite 1

-- 10,000 participant randomized Phase 2b study will evaluate Gritstone’s self-amplifying mRNA (samRNA) vaccine candidate containing Spike plus other viral targets with an approved vaccine against COVID-19 --